Non-Alcoholic Steatohepatitis (NASH) Market Trends and Opportunities Across 2026–2030
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Non-Alcoholic Steatohepatitis (NASH) Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The non-alcoholic steatohepatitis (nash) market has seen substantial growth in size recently. It is anticipated to expand from $6.06 billion in 2025 to $8.04 billion in 2026, progressing at a compound annual growth rate (CAGR) of 32.7%. This historical growth can be linked to several factors, including insufficient awareness about nash, the absence of truly effective treatment options, a strong reliance on lifestyle modifications, the high prevalence of metabolic disorders, and a fragmented market landscape.
The non-alcoholic steatohepatitis (NASH) market is projected for rapid expansion over the coming years. Its value is anticipated to reach $24.32 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 31.9%. This forecasted increase stems from progress in targeted therapies, a rise in healthcare spending, the wider acceptance of non-invasive diagnostic methods, the growth of pharmaceutical development pipelines, and an increase in R&D collaborations. Key trends shaping this period encompass the growing incidence of obesity and type 2 diabetes, the creation of non-invasive diagnostic instruments, intensified research into liver fibrosis treatments, an uptick in personalized and targeted drug therapies, and the broadening of hospital and retail pharmacy infrastructures.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp
What Drivers Are Influencing The Non-Alcoholic Steatohepatitis (NASH) Market?
The escalating incidence of obesity is propelling the demand within the non-alcoholic steatohepatitis (NASH) market. Obesity is characterized by an abnormal or excessive accumulation of fat that presents a health risk, or a body weight exceeding what is considered healthy or typical for an individual’s height. As the global obesity pandemic continues to rise, the prevalence of non-alcoholic fatty liver disease has grown, positioning NASH to potentially become the primary cause of severe liver disease in the coming decades, thereby fueling the requirement for NASH treatments and related pharmaceutical products. For instance, data from May 2025, released by the Government Digital Service, a UK-based government body, indicated that in 2023 to 2024, the prevalence of being overweight (including obesity) in adults was higher among men (69.7%) compared to women (59.2%), while the prevalence of obesity specifically in adults was higher among women (26.9%) than men (26.2%). Consequently, the growing number of obesity cases is expected to stimulate the expansion of the non-alcoholic steatohepatitis (NASH) market.
What Major Segment Divisions Exist Within The Non-Alcoholic Steatohepatitis (NASH) Market?
The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –
1) By Dosage Form: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
How Are Trends Shaping The Direction Of The Non-Alcoholic Steatohepatitis (NASH) Market?
Leading companies within the non-alcoholic steatohepatitis (NASH) market are engaged in developing thyroid hormone receptor-beta (THR-beta) agonists, designed to enhance liver metabolism, mitigate liver fat accumulation, and improve liver function. These thyroid hormone receptor-beta (THR-beta) agonists are compounds that specifically activate the thyroid hormone receptor-beta subtype, a crucial receptor involved in regulating metabolism, growth, and development. For instance, in March 2024, the Food and Drug Administration, a US-based regulatory body, approved Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist, as the inaugural treatment for adults with noncirrhotic NASH featuring moderate to advanced liver scarring (fibrosis). By selectively activating the THR-beta receptor, Rezdiffra contributes to the regulation of lipid metabolism, thereby leading to a reduction in intrahepatic triglycerides and overall liver fat accumulation.
Which Companies Are Leading Innovation In The Non-Alcoholic Steatohepatitis (NASH) Market?
Major companies operating in the non-alcoholic steatohepatitis (nash) market are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens
Read the full non-alcoholic steatohepatitis (nash) market report here:
Which Regions Are Expected To Experience Rapid Expansion In The Non-Alcoholic Steatohepatitis (NASH) Market?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2025. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Non-Alcoholic Steatohepatitis (NASH) Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis (NASH) Market 2026, By The Business Research Company
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Biomarkers Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
